Argenx rises after Q2 results beat driven by Vyvgart sales
BUZZ-Argenx rises after Q2 results beat driven by Vyvgart sales ** Shares in argenx ARGX.BR are up 4.1% after Q2 profit beats estimates
** Argenx posted Q2 total operating income of $1.54 billion, above average IBES estimates of $1.44 billion and Q2 operating profit of $494 million above estimates of $438.76 million
** Good results were driven by a 60% increase year-on-year in sales of its lead drug Vyvgart
** Kempen "would not be surprised if the operating and net margins continue to improve as a result of operational excellence, with the company ultimately landing at above industry averages"
** For J.P.Morgan, after these good results, the focus should remain on upcoming results for the expansion of Vyvgart in myositis
** Up to the previous session's close, shares were up 5.8% YTD
(Reporting by Lucie Barbier)
((Email: lucie.barbier@thomsonreuters.com))